These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3198329)

  • 1. Isomerism in iohexol and ioxilan. Analysis and implications.
    Foster SJ; Sovak M
    Invest Radiol; 1988 Sep; 23 Suppl 1():S106-9. PubMed ID: 3198329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stabilization of the hydrophilic sphere of iobitridol, a new nonionic iodinated contrast agent.
    Meyer D; Petta M; Fouchet MH; Vadel M; Schaefer M; Dugast-Zrihen M; Guillemot M
    Acta Radiol Suppl; 1996; 400():8-16. PubMed ID: 8619359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for improved contrast media. Ioxilan: updating design theory.
    Sovak M
    Invest Radiol; 1988 Sep; 23 Suppl 1():S79-83. PubMed ID: 3058636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urine profiles following intravenous diatrizoate, iohexol, or ioxilan in rats.
    Thomsen HS; Dorph S; Mygind T; Hemmingsen L; Holm J; Larsen S; Nielsen H; Rygaard H; Skaarup P
    Invest Radiol; 1988 Sep; 23 Suppl 1():S168-70. PubMed ID: 3198338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Do contrast media aggravate Fanconi's syndrome in rats? A comparison of diatrizoate, iohexol, and ioxilan.
    Thomsen HS; Dorph S; Mygind T; Nielsen H; Rygaard H; Larsen S; Skaarup P; Hemmingsen L; Holm J
    Invest Radiol; 1988 Sep; 23 Suppl 1():S164-7. PubMed ID: 3198337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stabilization of the hydrophilic sphere of iobitridol, an iodinated contrast agent, as revealed by experimental and computational investigations.
    Meyer D; Fouchet MH; Petta M; Carrupt PA; Gaillard P; Testa B
    Pharm Res; 1995 Nov; 12(11):1583-91. PubMed ID: 8592654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the systemic responses to rapid intravenous injections of ioxilan, iohexol, and diatrizoate in rabbits.
    Morris TW; Prentice L; Ventura J
    Invest Radiol; 1989 Apr; 24(4):294-7. PubMed ID: 2745009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nephropathy induced by intramuscularly administered glycerol and contrast media in rats. A comparison between diatrizoate, iohexol and ioxilan.
    Thomsen HS; Larsen S; Hemmingsen L; Holm J; Skaarup P
    Acta Radiol; 1989; 30(2):217-22. PubMed ID: 2923748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current contrast media and ioxilan. Comparative evaluation of vascular pain by aversion conditioning.
    Sovak M; Halkovich CA; Foster SJ
    Invest Radiol; 1988 Sep; 23 Suppl 1():S84-7. PubMed ID: 3198369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a new nonionic contrast agent, ioxilan, on human erythrocytes and the hemostatic and serum complement pathways.
    Parvez Z; Patel NB
    Invest Radiol; 1988 Sep; 23 Suppl 1():S182-5. PubMed ID: 3198340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous injection of ioxilan, iohexol and diatrizoate. Effects on urine profiles in the rat.
    Thomsen HS; Dorph S; Mygind T; Sovak M; Nielsen H; Rygaard H; Larsen S; Skaarup P; Hemmingsen L; Holm J
    Acta Radiol; 1988; 29(1):131-6. PubMed ID: 2964835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional and morphologic effects of ioxilan, iohexol, and diatrizoate on endothelial cells.
    Schneider KM; Ham KN; Friedhuber A; Rand MJ
    Invest Radiol; 1988 Sep; 23 Suppl 1():S147-9. PubMed ID: 3264276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RP-HPLC and NMR study of cis-trans isomerization of enalaprilat.
    Bouabdallah S; Trabelsi H; Ben Dhia T; Sabbah S; Bouzouita K; Khaddar R
    J Pharm Biomed Anal; 2003 Mar; 31(4):731-41. PubMed ID: 12644200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structure of the toxaphene compound 2,5-endo,6-exo,8,9,9,10,10-octachlorobornene-2: a temperature-dependent formation of two rotamers.
    Parlar H; Burhenne J; Coelhan M; Vetter W
    Environ Sci Technol; 2005 Mar; 39(6):1736-40. PubMed ID: 15819232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravascular contrast media and the blood-brain barrier. Testing the new nonionic agent ioxilan.
    Harnish PP; Krutchen A; Mukherji M
    Invest Radiol; 1989 Jan; 24(1):34-6. PubMed ID: 2917821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of retinolisomers by high-performance liquid chromatography not unequivocal up to now.
    Nöll GN; Kalinowski HO
    Vision Res; 1996 Jul; 36(13):1887-92. PubMed ID: 8759428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The risk of contrast media-induced ventricular fibrillation is low in canine coronary arteriography with ioxilan.
    Misumi K; Tateno O; Fujiki M; Miura N; Sakamoto H
    J Vet Med Sci; 2000 Apr; 62(4):421-6. PubMed ID: 10823730
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation and identification of peptide conformers by reversed-phase high-performance liquid chromatography and NMR at low temperature.
    Kálmán A; Thunecke F; Schmidt R; Schiller PW; Horváth C
    J Chromatogr A; 1996 Apr; 729(1-2):155-71. PubMed ID: 9004937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative determination of exo- and endo-iohexol in canine and feline samples using high performance liquid chromatography with ultraviolet detection.
    De Baere S; Smets P; Finch N; Heiene R; De Backer P; Daminet S; Croubels S
    J Pharm Biomed Anal; 2012 Mar; 61():50-6. PubMed ID: 22178335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ioxilan, a third generation low osmolality nonionic contrast medium. Systemic and renal hemodynamic effects.
    Katzberg RW; Donahue LA; Morris TW; Ventura JA; Krutchen AE; Proskin HM; Sovak M; Cos LR
    Invest Radiol; 1990 Jan; 25(1):46-51. PubMed ID: 2404899
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.